摘要
磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)/蛋白激酶B(protein kinase B,AKT)/哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)信号转导通路在多种肿瘤中异常激活,参与肿瘤细胞增殖、分化和凋亡等生命过程的调控,是抗肿瘤药物研发的重要靶点。对目前已应用于乳腺癌临床或处于临床试验阶段的PI3K/AKT/mTOR信号通路抑制剂进行归纳,并综述该通路抑制剂的联合用药策略,以期为不同亚型乳腺癌提供个体化靶向治疗方案。
The abnormal activation of phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT)/mammalian target of rapamycin(mTOR)pathway takes place in a variety of tumors.This pathway,which is an important target for the development of anti-tumor drugs,mediates the regulation of tumor cell proliferation,differentiation and apoptosis.This article summarized the PI3K/AKT/mTOR pathway inhibitors used in clinical practice and undergoing clinical trials,and also reviewed the combination strategy of several pathway inhibitors with other targeted drugs,which may offer personalized approach for the treatment of different breast cancer subtypes.
作者
卢训西
国琳玮
李小光
胡欣
LU Xunxi;GUO Linwei;LI Xiaoguang;HU Xin(Department of Breast Surgery,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2020年第2期154-160,共7页
China Oncology
基金
国家自然科学基金（81672601）
